



G Medical Innovations Holdings Ltd
ARBN 617 204 743

ASX Announcement

16 May 2019

NEWS ARTICLE CLARIFICATION

G Medical Innovations Holdings Ltd (ASX: GMV) (**G Medical** or the **Company**) would like to provide clarification in relation to an article published by news website 'The Jerusalem Post' on 15th April 2019.

It has recently come to the Company's attention that the article has incorrectly stated that the Company's G Medical Patch device has received FDA approval. The Company would like to clarify that the G Medical Patch device has not received FDA approval and that the FDA approval process is presently ongoing (refer to the Company's activities report for the quarter ended 31 March 2019 dated 30 April 2019).

The Company would like to take this opportunity to remind shareholders that the Company is unable to ensure the correctness of, or verify, material or information published by unrelated third parties and accordingly, shareholders are cautioned not to place reliance on information in respect to the Company obtained from third party sources, including online news platforms, and should refer to the Company's announcements on its ASX platform for information in respect to the Company.

-ENDS-

Board of Directors
G Medical Innovations Holdings Ltd

About G Medical Innovations

G Medical (**ASX: GMV**) was founded in August 2014, aiming to be at the forefront of the digital health revolution, developing the next generation of mobile health (mHealth) technologies. The Company leverages the experience and expertise of its Board to deliver best-in-class solutions to address this global opportunity.

The Company specialises in innovative next generation mobile and e-health solutions using its suite of proprietary devices and software solutions, as well as patient service operations, with a view to driving multiple and recurring revenue streams, across numerous verticals and territories.

For more information on G Medical, please visit www.gmedinnovations.com